Humana Insured Patients: Loyola Medicine is out of network with Humana. Humana is re-engaged in negotiations to reach a fair agreement. Learn more loyolamedicine.org/humana.

Loyola University Medical Center

Gottlieb Memorial Hospital

MacNeal Hospital

Back to homepage
myLoyola

Jeanine M Walenga, PhD

Clinical Pathology

Primary Contact

888-584-7888
Primary Contact
888-584-7888
Print Share

Services & Specialties

Areas of Specialization

  • Clinical Pathology

Locations & Contact

Primary Location

Loyola University Medical Center

2160 S First Ave
Maywood, IL 60153

View hours
Monday
8:00am - 5:00pm
Tuesday
8:00am - 5:00pm
Wednesday
8:00am - 5:00pm
Thursday
8:00am - 5:00pm
Friday
8:00am - 5:00pm
Saturday
8:00am - 5:00pm
Sunday
8:00am - 5:00pm
Loyola University Medical Center
708-216-2438 View Details

Education & Certifications

Education

Education:
University Deparis Sorbonne (1987)

Publications

  • The DOAC (direct oral anticoagulant) Dipstick reliably excludes residual FXa inhibitors levels in the preoperative setting. Vassart, J.; Tafur, A.; Durante, M.; Boucher, A. Y.; Morimont, L.; Walenga, J. M.; Harenberg, J.; Douxfils, J.; Thrombosis research
  • Prevention and management of venous thromboembolism. International Consensus Statement. Guidelines according to scientific evidence. Nicolaides, A. N.; Fareed, J.; Spyropoulos, A. C.; Kakkar, R. H. L.; Antignani, P. L.; Avgerinos, E.; Baekgaard, N.; Barber, E.; Bush, R. L.; Caprini, J. A.; Clarke-Pearson, D. L.; VAN Dreden, P.; Elalami, I.; Gerotziafas, G.; Gibbs, H.; Goldhaber, S.; Kakkos, S.; Lefkou, E.; Labropoulos, N.; Lopes, R. D.; Mansilha, A.; Papageorgiou, C.; Prandoni, P.; Ramacciotti, E.; Rognoni, C.; Urbanek, T.; Walenga, J. M.; International angiology : a journal of the International Union of Angiology
  • Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus Paper. Harenberg, J.; Gosselin, R. C.; Cuker, A.; Becattini, C.; Pabinger, I.; Poli, S.; Weitz, J.; Ageno, W.; Bauersachs, R.; Celap, I.; Choi, P.; Douketis, J.; Douxfils, J.; Elalamy, I.; Falanga, A.; Fareed, J.; Favaloro, E. J.; Gerotziafas, G.; Herkner, H.; Hetjens, S.; Heubner, L.; Klamroth, R.; Langer, F.; Lip, G. Y. H.; Grory, B. M.; Margetić, S.; Merrelaar, A.; Pikta, M.; Renne, T.; Schulman, S.; Schwameis, M.; Strbian, D.; Tafur, A.; Vassart, J.; Violi, F.; Walenga, J.; Weiss, C.; Thrombosis and haemostasis
  • Association of Angiopoetin-2 and TNF-α With Bleeding During Left Ventricular Assist Device Support: Analysis From the PREVENT Biorepository. Kim, G.; Sayer, G.; Ransom, J.; Keebler, M.; Katz, J.; Kilic, A.; Lindenfeld, J.; Egnaczyk, G.; Shah, P.; Brieke, A.; Walenga, J.; Crandall, D.; Farrar, D. J.; Sundareswaran, K.; Uriel, N.; ASAIO journal (American Society for Artificial Internal Organs : 1992)
  • Glycemic Control and Plasma Levels of Pro-Inflammatory and Pro-Thrombotic Biomarkers in Diabetic Patients Presenting with Acute Pulmonary Embolism. O'Hara, A.; Pozin, J.; Darki, A.; Siddiqui, F.; Hoppensteadt, D.; Walenga, J.; Fareed, J.; Kantarcioglu, B.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Enhanced Thrombin Formation in Patients With Ventricular Assist Devices Experiencing Bleeding: Insights From the Multicenter PREVENT Study. Jeske, W.; Ransom, J.; Katz, J. N.; Kilic, A.; Lindenfeld, J.; Egnaczyk, G.; Shah, P.; Brieke, A.; Uriel, N.; Crandall, D.; Farrar, D. J.; Walenga, J. M.; ASAIO journal (American Society for Artificial Internal Organs : 1992)
  • Inflammatory cytokines in robot-assisted thoracic surgery versus video-assisted thoracic surgery. Jaradeh, M.; Curran, B.; Poulikidis, K.; Rodrigues, A.; Jeske, W.; Abdelsattar, Z. M.; Lubawski, J.; Walenga, J.; Vigneswaran, W. T.; Journal of thoracic disease
  • Predictive Role of Blood Cellular Indices and Their Relationship with Endogenous Glycosaminoglycans as Determinants of Inflammatory Biomarkers in Pulmonary Embolism. Kantarcioglu, B.; Darki, A.; Siddiqui, F.; Krupa, E.; Vural, M.; Kacmaz, M.; Hoppensteadt, D.; Iqbal, O.; Jeske, W.; Walenga, J.; Adiguzel, C.; Fareed, J.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Multiplex genome editing of mammalian cells for producing recombinant heparin. Thacker, B. E.; Thorne, K. J.; Cartwright, C.; Park, J.; Glass, K.; Chea, A.; Kellman, B. P.; Lewis, N. E.; Wang, Z.; Di Nardo, A.; Sharfstein, S. T.; Jeske, W.; Walenga, J.; Hogwood, J.; Gray, E.; Mulloy, B.; Esko, J. D.; Glass, C. A.; Metabolic engineering
  • An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination. Kantarcioglu, B.; Iqbal, O.; Walenga, J. M.; Lewis, B.; Lewis, J.; Carter, C. A.; Singh, M.; Lievano, F.; Tafur, A.; Ramacciotti, E.; Gerotziafas, G. T.; Jeske, W.; Fareed, J.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Angiopoietin-2 correlates with pulmonary embolism severity, right ventricular dysfunction, and intensive care unit admission. Newman, J.; Brailovsky, Y.; Allen, S.; Bontekoe, E.; Masic, D.; Walenga, J.; Fareed, J.; Darki, A.; Vascular medicine (London, England)
  • Protein C Pathway, Inflammation, and Pump Thrombosis in Patients With Left Ventricular Assist Devices. Walenga, J. M.; Torres, T. A.; Jeske, W. P.; Schwartz, J.; Escalante, V.; Newman, J. D.; Bakhos, M.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Heparin: Much more than anti-IIa/anti-Xa. Walenga, J. M.; Journal de medecine vasculaire
  • Zika and Chikungunya Virus and Risk for Venous Thromboembolism. Ramacciotti, E.; Agati, L. B.; Aguiar, V. C. R.; Wolosker, N.; Guerra, J. C.; de Almeida, R. P.; Alves, J. C.; Lopes, R. D.; Wakefield, T. W.; Comerota, A. J.; Walenga, J.; Fareed, J.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Bovine Mucosal Heparins Are Comparable to Porcine Mucosal Heparin at USP Potency Adjusted Levels. Jeske, W.; Kouta, A.; Farooqui, A.; Siddiqui, F.; Rangnekar, V.; Niverthi, M.; Laddu, R.; Hoppensteadt, D.; Iqbal, O.; Walenga, J.; Fareed, J.; Frontiers in medicine
  • Profiling Heparin-Induced Thrombocytopenia (HIT) Antibodies in Hospitalized Patients With and Without Diabetes. Prechel, M.; Hudec, S.; Lowden, E.; Escalante, V.; Emanuele, N.; Emanuele, M.; Walenga, J. M.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Medical management of stable peripheral artery disease: the COMPASS trial. Perspectives from a vascular standpoint. Ramacciotti, E.; Castelli, V.; Walenga, J.; Fareed, J.; International angiology : a journal of the International Union of Angiology
  • Identification of Novel Hemostatic Biomarkers of Adverse Clinical Events in Patients Implanted With a Continuous-Flow Left Ventricular Assist Device. McClane, N.; Jeske, W.; Walenga, J. M.; Escalante, V.; Hoppensteadt, D.; Schwartz, J.; Bakhos, M.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Sulodexide for the extended treatment of venous thromboembolism. Walenga, J. M.; Fareed, J.; Ramacciotti, E.; International angiology : a journal of the International Union of Angiology
  • Blood cell microparticles as biomarkers of hemostatic abnormalities in patients with implanted cardiac assist devices. Jeske, W. P.; Walenga, J. M.; Menapace, B.; Schwartz, J.; Bakhos, M.; Biomarkers in medicine
  • North American Thrombosis Forum, AF Action Initiative Consensus Document. Ruff, C. T.; Ansell, J. E.; Becker, R. C.; Benjamin, E. J.; Deicicchi, D. J.; Mark Estes, N. A.; Ezekowitz, M. D.; Fanikos, J.; Fareed, J.; Garcia, D.; Giugliano, R. P.; Goldhaber, S. Z.; Granger, C.; Healey, J. S.; Hull, R.; Hylek, E. M.; Libby, P.; Lopes, R. D.; Mahaffey, K. W.; Mega, J.; Piazza, G.; Sasahara, A. A.; Sorond, F. A.; Spyropoulos, A. C.; Walenga, J. M.; Weitz, J. I.; The American journal of medicine
  • Complexes of platelet factor 4 and heparin activate Toll-like receptor 4. Prechel, M. M.; Walenga, J. M.; Journal of thrombosis and haemostasis : JTH
  • Sustained release of tissue factor following thrombosis of lower limb trauma. Walenga, J. M.; Kaiser, P. C.; Prechel, M. M.; Hoppensteadt, D.; Jeske, W. P.; Misselwitz, F.; Bacher, P.; Lassen, M. R.; Fareed, J.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Production of Anti-platelet Factor 4/Heparin Complex Antibodies After Cardiovascular Surgery. Matsuo, T.; Motohashi, S.; Wanaka, K.; Walenga, J. M.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer. Walenga, J. M.; Lyman, G. H.; Critical reviews in oncology/hematology
  • Increase in cardiac myosin binding protein-C plasma levels is a sensitive and cardiac-specific biomarker of myocardial infarction. Govindan, S.; Kuster, D. W.; Lin, B.; Kahn, D. J.; Jeske, W. P.; Walenga, J. M.; Leya, F.; Hoppensteadt, D.; Fareed, J.; Sadayappan, S.; American journal of cardiovascular disease
  • Apixaban as an alternate oral anticoagulant for the management of patients with heparin-induced thrombocytopenia. Walenga, J. M.; Prechel, M.; Hoppensteadt, D.; Escalante, V.; Chaudhry, T.; Jeske, W. P.; Bakhos, M.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia. Prechel, M. M.; Walenga, J. M.; Thrombosis journal
  • Anticoagulant and Antithrombotic Actions of AVE5026, an Enriched Anti-Xa Hemisynthetic Ultra-Low-Molecular-Weight Heparin. Hoppensteadt, D. A.; Gray, A.; Jeske, W. P.; Walenga, J. M.; Fareed, J.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Left ventricular assist device-induced coagulation and platelet activation and effect of the current anticoagulant therapy regimen. Ashbrook, M.; Walenga, J. M.; Schwartz, J.; Heroux, A.; Jeske, W. P.; Escalante, V.; Bakhos, M.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Comparative studies on branded enoxaparin and a US generic version of enoxaparin. Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D.; Cunanan, J.; Khan, H.; Escalante, V.; Fareed, J.; Bakhos, M.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Nonhemostatic adverse effects of anticoagulants and antiplatelet agents. Walenga, J. M.; Thethi, I.; Lewis, B. E.; Seminars in thrombosis and hemostasis
  • Heparin-induced thrombocytopenia: an update. Prechel, M.; Walenga, J. M.; Seminars in thrombosis and hemostasis
  • A colorimetric, metabolic dye reduction assay detects highly activated platelets: application in the diagnosis of heparin-induced thrombocytopenia. Prechel, M. M.; Escalante, V.; Drenth, A. F.; Walenga, J. M.; Platelets
  • A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin. Jeske, W. P.; Hoppensteadt, D.; Gray, A.; Walenga, J. M.; Cunanan, J.; Myers, L.; Fareed, J.; Bayol, A.; Rigal, H.; Viskov, C.; Thrombosis research
  • Low molecular weight heparins differ substantially: impact on developing biosimilar drugs. Walenga, J. M.; Jackson, C. M.; Kessler, C. M.; Seminars in thrombosis and hemostasis
  • Functionality of fondaparinux (pentasaccharide) depends on clinical antithrombin levels. Jeske, W. P.; Walenga, J. M.; Samama, M. M.; Hoppensteadt, D.; Mayuga, M.; Fareed, J.; Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  • An open label, non-randomized, prospective clinical trial evaluating the immunogenicity of branded enoxaparin versus biosimilars in healthy volunteers. Gomes, M.; Ramacciotti, E.; Hoppensteadt, D.; Walenga, J. M.; Lewis, B.; Thethi, I.; Fareed, J.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Pharmacology of argatroban. Jeske, W. P.; Fareed, J.; Hoppensteadt, D. A.; Lewis, B.; Walenga, J. M.; Expert review of hematology
  • Laboratory methods and management of patients with heparin-induced thrombocytopenia. Prechel, M.; Jeske, W. P.; Walenga, J. M.; Methods in molecular biology (Clifton, N.J.)
  • Drug and dietary interactions of the new and emerging oral anticoagulants. Walenga, J. M.; Adiguzel, C.; International journal of clinical practice
  • In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative. Kuziej, J.; Litinas, E.; Hoppensteadt, D. A.; Liu, D.; Walenga, J. M.; Fareed, J.; Jeske, W.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Profiling of heparin-induced thrombocytopenia antibody levels in patients with and without diabetes. Diaz, J.; Prechel, M.; Emanuele, M.; Emanuele, N.; Walenga, J. M.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Physiological changes in membrane-expressed platelet factor 4: implications in heparin-induced thrombocytopenia. Prechel, M. M.; Jeske, W. P.; Walenga, J. M.; Thrombosis research
  • Comparative anticoagulant and platelet modulatory effects of enoxaparin and sulodexide. Adiguzel, C.; Iqbal, O.; Hoppensteadt, D.; Jeske, W.; Cunanan, J.; Litinas, E.; He Zhu; Walenga, J. M.; Fareed, J.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products. Adiguzel, C.; Jeske, W. P.; Hoppensteadt, D.; Walenga, J. M.; Bansal, V.; Fareed, J.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia. Walenga, J. M.; Prechel, M.; Jeske, W. P.; Hoppensteadt, D.; Maddineni, J.; Iqbal, O.; Messmore, H. L.; Bakhos, M.; British journal of haematology
  • Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effect on coagulation factor testing. Walenga, J. M.; Drenth, A. F.; Mayuga, M.; Hoppensteadt, D. A.; Prechel, M.; Harder, S.; Watanabe, H.; Osakabe, M.; Breddin, H. K.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update. Prechel, M.; Walenga, J. M.; Seminars in thrombosis and hemostasis
  • Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins. Jeske, W. P.; Walenga, J. M.; Hoppensteadt, D. A.; Vandenberg, C.; Brubaker, A.; Adiguzel, C.; Bakhos, M.; Fareed, J.; Seminars in thrombosis and hemostasis
  • The future of anticoagulation. Hoppensteadt, D. A.; Jeske, W.; Walenga, J.; Fareed, J.; Seminars in respiratory and critical care medicine
  • The relationship between the antiphospholipid syndrome and heparin-induced thrombocytopenia. Hoppensteadt, D. A.; Walenga, J. M.; Hematology/oncology clinics of North America
  • Inflammatory and hemostatic activation in patients undergoing off-pump coronary artery bypass grafting. Untch, B. R.; Jeske, W. P.; Schwartz, J.; Botkin, S.; Prechel, M.; Walenga, J. M.; Bakhos, M.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Non-anticoagulant effects of unfractionated and low-molecular weight heparins. Walenga, J. M.; Clinical advances in hematology & oncology : H&O
  • Heparin oligosaccharides as potential therapeutic agents in senile dementia. Ma, Q.; Cornelli, U.; Hanin, I.; Jeske, W. P.; Linhardt, R. J.; Walenga, J. M.; Fareed, J.; Lee, J. M.; Current pharmaceutical design
  • Isolation and characterization of heparin from tuna skins. Jeske, W. P.; McDonald, M. K.; Hoppensteadt, D. A.; Bau, E. C.; Mendes, A.; Dietrich, C. P.; Walenga, J. M.; Coyne, E.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications. Maddineni, J.; Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D. A.; Fareed, J.; Wahi, R.; Bick, R. L.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. Ma, Q.; Tobu, M.; Schultz, C.; Jeske, W.; Hoppensteadt, D.; Walenga, J.; Cornelli, U.; Lee, J.; Linhardt, R.; Hanin, I.; Fareed, J.; Thrombosis research
  • Update on the clinical applications of argatroban. Fareed, J.; Jeske, W. P.; Hoppensteadt, D. A.; Walenga, J. M.; Future cardiology
  • Activation of platelets by heparin-induced thrombocytopenia antibodies in the serotonin release assay is not dependent on the presence of heparin. Prechel, M. M.; McDonald, M. K.; Jeske, W. P.; Messmore, H. L.; Walenga, J. M.; Journal of thrombosis and haemostasis : JTH
  • Unfractionated heparin compared with low-molecular-weight heparin as related to heparin-induced thrombocytopenia. Walenga, J. M.; Prechel, M.; Jeske, W. P.; Bakhos, M.; Current opinion in pulmonary medicine
  • Short- and long-acting synthetic pentasaccharides as antithrombotic agents. Walenga, J. M.; Jeske, W. P.; Fareed, J.; Expert opinion on investigational drugs
  • Pharmacology of argatroban. Jeske, W.; Walenga, J. M.; Lewis, B. E.; Fareed, J.; Expert opinion on investigational drugs
  • Emerging anticoagulant and thrombolytic drugs. Iqbal, O.; Aziz, S.; Hoppensteadt, D. A.; Ahmad, S.; Walenga, J. M.; Bakhos, M.; Fareed, J.; Expert opinion on emerging drugs
  • Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization. Iqbal, O.; Tobu, M.; Aziz, S.; Gerdisch, M.; Da Valle, M.; Demir, M.; Hoppensteadt, D. A.; Ahmad, S.; Walenga, J. M.; Fareed, J.; Journal of cardiac surgery
  • Development of generic low molecular weight heparins: a perspective. Fareed, J.; Leong, W.; Hoppensteadt, D. A.; Jeske, W. P.; Walenga, J.; Bick, R. L.; Hematology/oncology clinics of North America
  • Generic low-molecular-weight heparins: some practical considerations. Fareed, J.; Leong, W. L.; Hoppensteadt, D. A.; Jeske, W. P.; Walenga, J.; Wahi, R.; Bick, R. L.; Seminars in thrombosis and hemostasis
  • Monitoring the new antithrombotic drugs. Walenga, J. M.; Hoppensteadt, D. A.; Seminars in thrombosis and hemostasis
  • Decreased prevalence of heparin-induced thrombocytopenia with low-molecular-weight heparin and related drugs. Walenga, J. M.; Jeske, W. P.; Prechel, M. M.; Bacher, P.; Bakhos, M.; Seminars in thrombosis and hemostasis
  • Newer insights on the mechanism of heparin-induced thrombocytopenia. Walenga, J. M.; Jeske, W. P.; Prechel, M. M.; Bakhos, M.; Seminars in thrombosis and hemostasis
  • Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: implications in the HIT pathogenesis. Ahmad, S.; Untch, B.; Haas, S.; Hoppensteadt, D. A.; Misselwitz, F.; Messmore, H. L.; Walenga, J. M.; Fareed, J.; Molecular and cellular biochemistry
  • Factor Xa inhibitors. Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D.; Fareed, J.; Methods in molecular medicine
  • Laboratory methods for heparin-induced thrombocytopenia. Prechel, M.; Jeske, W. P.; Walenga, J. M.; Methods in molecular medicine
  • Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia. Jeske, W. P.; Walenga, J. M.; Methods in molecular medicine
  • Argatroban use during pediatric interventional cardiac catheterization. Cetta, F.; Graham, L. C.; Wrona, L. L.; Arruda, M. J.; Walenga, J. M.; Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
  • Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice. Fareed, J.; Hoppensteadt, D.; Walenga, J.; Iqbal, O.; Ma, Q.; Jeske, W.; Sheikh, T.; Clinical pharmacokinetics
  • Bleeding complications with glycoprotein IIb/IIIa inhibitors. Iqbal, O.; Walenga, J. M.; Lewis, B. E.; Bakhos, M.; Drugs of today (Barcelona, Spain : 1998)
  • Argatroban in HIT type II and acute coronary syndrome. Lewis, B. E.; Walenga, J. M.; Pathophysiology of haemostasis and thrombosis
  • An overview of the direct thrombin inhibitor argatroban. Walenga, J. M.; Pathophysiology of haemostasis and thrombosis
  • Factor Xa inhibitors: today and beyond. Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D.; Fareed, J.; Current opinion in investigational drugs (London, England : 2000)
  • Investigations of the immunoglobulin subtype transformation of anti-heparin-platelet factor 4 antibodies during treatment with a low-molecular-weight heparin (clivarin) in orthopedic patients. Ahmad, S.; Bacher, H. P.; Lassen, M. R.; Hoppensteadt, D. A.; Leitz, H.; Misselwitz, F.; Walenga, J. M.; Fareed, J.; Archives of pathology & laboratory medicine
  • Heparin-induced thrombocytopenia with associated thrombosis in children after the Fontan operation: report of two cases. Porcelli, R.; Moskowitz, B. C.; Cetta, F.; Graham, L. C.; Godwin, J. E.; Eidem, B. W.; Prechel, M. M.; Walenga, J. M.; Texas Heart Institute journal
  • Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation. Hoppensteadt, D.; Walenga, J. M.; Fareed, J.; Bick, R. L.; Hematology/oncology clinics of North America
  • Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other adverse effects of heparin-type therapy. Walenga, J. M.; Frenkel, E. P.; Bick, R. L.; Hematology/oncology clinics of North America
  • Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies. Ahmad, S.; Haas, S.; Hoppensteadt, D. A.; Lietz, H.; Reid, U.; Bender, N.; Messmore, H. L.; Misselwitz, F.; Bacher, P.; Gaikwad, B. S.; Jeske, W. P.; Walenga, J. M.; Fareed, J.; Thrombosis research
  • Monitoring of argatroban in ARG310 study: potential recommendations for its use in interventional cardiology. Iqbal, O.; Ahmad, S.; Lewis, B. E.; Walenga, J. M.; Rangel, Y.; Fareed, J.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia. Jeske, W. P.; Walenga, J. M.; Current opinion in investigational drugs (London, England : 2000)
  • Development of a non-human primate sub-clinical model of heparin-induced thrombocytopenia: platelet responses to human anti-heparin-platelet factor 4 antibodies. Untch, B.; Ahmad, S.; Messmore, H. L.; Schultz, C. L.; Ma, Q.; Hoppensteadt, D. A.; Walenga, J. M.; Fareed, J.; Thrombosis research
  • Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Walenga, J. M.; Ahmad, S.; Hoppensteadt, D.; Iqbal, O.; Hursting, M. J.; Lewis, B. E.; Thrombosis research
  • Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. The pathogenic role of IgG. Untch, B.; Ahmad, S.; Jeske, W. P.; Messmore, H. L.; Hoppensteadt, D. A.; Walenga, J. M.; Lietz, H.; Fareed, J.; Thrombosis research
  • Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Walenga, J. M.; Jeske, W. P.; Samama, M. M.; Frapaise, F. X.; Bick, R. L.; Fareed, J.; Expert opinion on investigational drugs
  • The hemostatic effects of warfarin titration in post CABG patients in comparison to placebo treatment. Walenga, J. M.; Hoppensteadt, D.; Pifarré, R.; Fox, N. L.; Forman, S.; Hunninghake, D. B.; Campeau, L.; Herd, J. A.; Hoogwerf, B. J.; Hickey, A.; Probstfield, J. L.; Terrin, M. L.; Journal of thrombosis and thrombolysis
  • Evaluation of a new point of care heparin test for cardiopulmonary bypass: the TAS heparin management test. Wallock, M.; Jeske, W. P.; Bakhos, M.; Walenga, J. M.; Perfusion
  • Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist. Ahmad, S.; Jeske, W. P.; Ma, Q.; Walenga, J. M.; Fareed, J.; Thrombosis research
  • Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Lewis, B. E.; Wallis, D. E.; Berkowitz, S. D.; Matthai, W. H.; Fareed, J.; Walenga, J. M.; Bartholomew, J.; Sham, R.; Lerner, R. G.; Zeigler, Z. R.; Rustagi, P. K.; Jang, I. K.; Rifkin, S. D.; Moran, J.; Hursting, M. J.; Kelton, J. G.; ARG-911 Study Investigators; Circulation
  • Synthetic heparin pentasaccharide depolymerization by heparinase I: molecular and biological implications. Daud, A. N.; Ahsan, A.; Iqbal, O.; Walenga, J. M.; Silver, P. J.; Ahmad, S.; Fareed, J.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • The impact of antithrombin (H) concentrate infusions on pulmonary function in the acute phase of thermal injury. Kowal-Vern, A.; Walenga, J. M.; McGill, V.; Gamelli, R. L.; Burns : journal of the International Society for Burn Injuries
  • Antithrombin(H) concentrate infusions are safe and effective in patients with thermal injuries. Kowal-Vern, A.; McGill, V.; Walenga, J. M.; Gamelli, R. L.; The Journal of burn care & rehabilitation
  • Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia. Walenga, J. M.; Jeske, W. P.; Messmore, H. L.; Journal of thrombosis and thrombolysis
  • Human anti-heparin-platelet factor 4 antibodies are capable of activating primate platelets: towards the development of a HIT model in primates. Ahmad, S.; Jeske, W. P.; Walenga, J. M.; Aldabbagh, A.; Iqbal, O.; Fareed, J.; Thrombosis research
  • Pharmacokinetics of argatroban in primates: evidence on endogenous uptake. Ahmad, S.; Yang, L. H.; Ahsan, A.; Fu, K.; Iqbal, O.; Hoppensteadt, D. A.; Lewis, B. E.; Walenga, J. M.; Fareed, J.; International angiology : a journal of the International Union of Angiology
  • Soluble P-selectin in human plasma: effect of anticoagulant matrix and its levels in patients with cardiovascular disorders. Amin, H. M.; Ahmad, S.; Walenga, J. M.; Hoppensteadt, D. A.; Leitz, H.; Fareed, J.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Vascular damage correlates between heparin-induced thrombocytopenia and the antiphospholipid syndrome. Walenga, J. M.; Michal, K.; Hoppensteadt, D.; Wood, J. J.; Robinson, J. A.; Bick, R. L.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Heparin-induced thrombocytopenic potential of GAG and non-GAG-based antithrombotic agents. Jeske, W. P.; Jay, A. M.; Haas, S.; Walenga, J. M.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Antithrombin agents: the new class of anticoagulant and antithrombotic drugs. Fareed, J.; Lewis, B. E.; Callas, D. D.; Hoppensteadt, D. A.; Walenga, J. M.; Bick, R. L.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Soluble adhesion molecules in the HIT syndrome: pathophysiologic role and therapeutic modulation. Fareed, J.; Walenga, J. M.; Hoppensteadt, D. A.; Jeske, W. P.; Ahmad, S.; Lietz, H.; McKenna, R.; Messmore, H. L.; Haas, S.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Functional heterogeneity of antiheparin-platelet factor 4 antibodies: implications in the pathogenesis of the HIT syndrome. Ahmad, S.; Walenga, J. M.; Jeske, W. P.; Cella, G.; Fareed, J.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Laboratory diagnosis of heparin-induced thrombocytopenia. Walenga, J. M.; Jeske, W. P.; Fasanella, A. R.; Wood, J. J.; Ahmad, S.; Bakhos, M.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies. Ahmad, S.; Jeske, W. P.; Walenga, J. M.; Hoppensteadt, D. A.; Wood, J. J.; Herbert, J. M.; Messmore, H. L.; Fareed, J.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Simultaneous monitoring of argatroban and its major metabolite using an HPLC method: potential clinical applications. Ahmad, S.; Ahsan, A.; George, M.; Iqbal, O.; Jeske, W. P.; McKenna, R.; Lewis, B. E.; Walenga, J. M.; Fareed, J.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Clinical laboratory monitoring of a synthetic antithrombin agent, argatroban, using high performance liquid chromatography and functional methods. Ahmad, S.; Iqbal, O.; Ahsan, A.; Hoppensteadt, D. A.; Lewis, B. E.; Walenga, J. M.; Fareed, J.; International angiology : a journal of the International Union of Angiology
  • Antithrombin III concentrate in the acute phase of thermal injury. Kowal-Vern, A.; McGill, V.; Walenga, J. M.; Gamelli, R. L.; Burns : journal of the International Society for Burn Injuries
  • Laboratory monitoring of pentasaccharide in a dog model of hemodialysis. Hoppensteadt, D. A.; Jeske, W. P.; Walenga, J. M.; Fu, K.; Yang, L. H.; Ing, T. S.; Herbert, J. M.; Fareed, J.; Thrombosis research
  • Hemostatic effects of 1 mg daily warfarin on post CABG patients. Post CABG Studies Investigators. Walenga, J. M.; Hoppensteadt, D.; Pifarré, R.; Cressman, M. D.; Hunninghake, D. B.; Fox, N. L.; Terrin, M. L.; Probstfield, J. L.; Journal of thrombosis and thrombolysis
  • Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT. Walenga, J. M.; Jeske, W. P.; Wallis, D. E.; Bakhos, M.; Lewis, B. E.; Leya, F.; Fareed, J.; Seminars in thrombosis and hemostasis
  • Coagulation laboratory testing in patients treated with argatroban. Walenga, J. M.; Fasanella, A. R.; Iqbal, O.; Hoppensteadt, D. A.; Ahmad, S.; Wallis, D. E.; Bakhos, M.; Seminars in thrombosis and hemostasis
  • Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis of heparin-induced thrombocytopenia. Izban, K. F.; Lietz, H. W.; Hoppensteadt, D. A.; Jeske, W. P.; Fareed, J.; Bakhos, M.; Walenga, J. M.; Seminars in thrombosis and hemostasis
  • Laboratory tests for the diagnosis of heparin-induced thrombocytopenia. Walenga, J. M.; Jeske, W. P.; Fasanella, A. R.; Wood, J. J.; Bakhos, M.; Seminars in thrombosis and hemostasis
  • Selectins in the HIT syndrome: pathophysiologic role and therapeutic modulation. Fareed, J.; Walenga, J. M.; Hoppensteadt, D. A.; Jeske, W. P.; Lietz, H.; Ahmad, S.; Callas, D.; Messmore, H. L.; Haas, S.; Seminars in thrombosis and hemostasis
  • Antithrombin agents as anticoagulants and antithrombotics: implications in drug development. Fareed, J.; Callas, D.; Hoppensteadt, D. A.; Lewis, B. E.; Bick, R. L.; Walenga, J. M.; Seminars in hematology
  • Laboratory tests for heparin-induced thrombocytopenia: a multicenter study. Walenga, J. M.; Jeske, W. P.; Wood, J. J.; Ahmad, S.; Lewis, B. E.; Bakhos, M.; Seminars in hematology
  • Low molecular weight heparins: are they different? Fareed, J.; Hoppensteadt, D.; Jeske, W.; Clarizio, R.; Walenga, J. M.; The Canadian journal of cardiology
  • Low-molecular-weight heparins: pharmacologic profile and product differentiation. Fareed, J.; Jeske, W.; Hoppensteadt, D.; Clarizio, R.; Walenga, J. M.; The American journal of cardiology
  • Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy. Walenga, J. M.; Bick, R. L.; The Medical clinics of North America
  • Antithrombin agents as anticoagulants and antithrombotics. Implications in drug development. Fareed, J.; Callas, D.; Hoppensteadt, D. A.; Walenga, J. M.; Bick, R. L.; The Medical clinics of North America
  • Molecular markers of hemostatic activation and inflammation following major injury: effect of therapy with IFN-gamma. Dries, D. J.; Walenga, J. M.; Hoppensteadt, D.; Fareed, J.; Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
  • Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets. Jeske, W. P.; Walenga, J. M.; Szatkowski, E.; Ero, M.; Herbert, J. M.; Haas, S.; Bakhos, M.; Thrombosis research
  • Trauma and thermal injury: comparison of hemostatic and cytokine changes in the acute phase of injury. Kowal-Vern, A.; Sharp-Pucci, M. M.; Walenga, J. M.; Dries, D. J.; Gamelli, R. L.; The Journal of trauma
  • Efficacy of pentasaccharide in a dog model of hemodialysis. Hoppensteadt, D. A.; Jeske, W. P.; Walenga, J. M.; Fu, K.; Yang, L. H.; Ing, T.; Herbert, J. M.; Fareed, J.; Thrombosis research
  • Current status on new anticoagulant and antithrombotic drugs and devices. Walenga, J. M.; Fareed, J.; Current opinion in pulmonary medicine
  • Low molecular weight heparins: a developmental perspective. Fareed, J.; Hoppensteadt, D.; Jeske, W.; Clarizio, R.; Walenga, J. M.; Expert opinion on investigational drugs
  • Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. Walenga, J. M.; Jeske, W. P.; Bara, L.; Samama, M. M.; Fareed, J.; Thrombosis research
  • Postburn edema and related changes in interleukin-2, leukocytes, platelet activation, endothelin-1, and C1 esterase inhibitor. Kowal-Vern, A.; Walenga, J. M.; Sharp-Pucci, M.; Hoppensteadt, D.; Gamelli, R. L.; The Journal of burn care & rehabilitation
  • Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Lewis, B. E.; Walenga, J. M.; Wallis, D. E.; Seminars in thrombosis and hemostasis
  • Efficacy of aprotinin with various anticoagulant agents in cardiopulmonary bypass. Terrell, M. R.; Walenga, J. M.; Koza, M. J.; Pifarré, R.; The Annals of thoracic surgery
  • Aprotinin modulation of platelet activation in patients undergoing cardiopulmonary bypass operations. Primack, C.; Walenga, J. M.; Koza, M. J.; Shankey, T. V.; Pifarre R; The Annals of thoracic surgery
  • Are the available low-molecular-weight heparin preparations the same? Fareed, J.; Jeske, W.; Hoppensteadt, D.; Clarizio, R.; Walenga, J. M.; Seminars in thrombosis and hemostasis
  • Successful treatment of heparin-associated thrombocytopenia and thrombosis using Hirulog. Chamberlin, J. R.; Lewis, B.; Leya, F.; Wallis, D.; Messmore, H.; Hoppensteadt, D.; Walenga, J. M.; Moran, S.; Fareed, J.; McKiernan, T.; The Canadian journal of cardiology
  • Comparative study on the use of anticoagulants heparin and recombinant hirudin in a rabbit traumatic anastomosis model. Fu, K.; Izquierdo, R.; Walenga, J. M.; Fareed, J.; Thrombosis research
  • Flow cytometric evaluation of platelet activation by ionic or nonionic contrast media and modulation by heparin and recombinant hirudin. Koza, M. J.; Shankey, T. C.; Walenga, J. M.; Moncada, R.; Fareed, J.; Pifarre, R.; Investigative radiology
  • TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. Hoppensteadt, D. A.; Walenga, J. M.; Fasanella, A.; Jeske, W.; Fareed, J.; Thrombosis research
  • Procoagulant and anticoagulant effects of intravascular contrast media as assessed by thromboelastography. Iqbal, O.; Jeske, W.; Hoppensteadt, D.; Koza, M.; Walenga, J. M.; Fareed, J.; Moncada, R.; Seminars in thrombosis and hemostasis
  • Thromboelastographic analysis of patients receiving aprotinin with comparisons to platelet aggregation and other assays. Koza, M. J.; Walenga, J. M.; Khenkina, Y. N.; Sullivan, H. J.; Montoya, A.; Pifarre, R.; Seminars in thrombosis and hemostasis
  • The approach of thromboelastography in the monitoring of new synthetic antithrombotic agents, GL-522 and GL-2021. Iqbal, O.; Jeske, W.; Hoppensteadt, D.; Walenga, J. M.; Fareed, J.; Seminars in thrombosis and hemostasis
  • Evaluation of hemostatic and fibrinolytic alterations associated with daily administration of low-molecular-weight heparin for a 12-week period. Lojewski, B.; Bacher, P.; Iqbal, O.; Walenga, J. M.; Hoppensteadt, D.; Leya, F.; Fareed, J.; Seminars in thrombosis and hemostasis
  • Impact of biotechnology in the diagnostic and therapeutic management of cardiovascular disorders. Fareed, J.; Hoppensteadt, D.; Iyer, L.; Koza, M.; Walenga, J. M.; Bermes, E.; Advances in experimental medicine and biology
  • Evaluation of CGP 39393 as the anticoagulant in cardiopulmonary bypass operation in a dog model. Walenga, J. M.; Koza, M. J.; Park, S. J.; Terrell, M. R.; Pifarré, R.; The Annals of thoracic surgery
  • Automation and quality control in the coagulation laboratory. Walenga, J. M.; Fareed, J.; Clinics in laboratory medicine
  • Current trends in the development of anticoagulant and antithrombotic drugs. Fareed, J.; Hoppensteadt, D.; Walenga, J. M.; Bick, R. L.; The Medical clinics of North America
  • Interleukin-2 and interleukin-6 in relation to burn wound size in the acute phase of thermal injury. Kowal-Vern, A.; Walenga, J. M.; Hoppensteadt, D.; Sharp-Pucci, M.; Gamelli, R. L.; Journal of the American College of Surgeons
  • Investigation of a thrombin inhibitor peptide as an alternative to heparin in cardiopulmonary bypass surgery. Chomiak, P. N.; Walenga, J. M.; Koza, M. J.; Reilly, T. M.; Turlapathy, P.; Pifarre, R.; Circulation
  • The antithrombotic and anticoagulant effects of a synthetic tripeptide and recombinant hirudin in various animal models. Bacher, P.; Walenga, J. M.; Iqbal, O.; Bajusz, S.; Breddin, K.; Fareed, J.; Thrombosis research
  • A simulated post-angioplasty low molecular weight heparin schedule in a non-human primate model. Bacher, P.; Iqbal, O.; Lojewski, B.; Walenga, J. M.; Leya, F.; Fareed, J.; Thrombosis research
  • Modulation of endothelial and platelet function by a polydeoxyribonucleotide derived drug "defibrotide". A dual mechanism in the control of vascular pathology. Bacher, P.; Kindel, G.; Walenga, J. M.; Fareed, J.; Thrombosis research
  • Evaluation of a low molecular weight heparin as an anticoagulant in a model of cardiopulmonary bypass surgery. Koza, M. J.; Messmore, H. L.; Wallock, M. E.; Walenga, J. M.; Pifarre, R.; Thrombosis research
  • Effects of aprotinin on anticoagulant monitoring: implications in cardiovascular surgery. Najman, D. M.; Walenga, J. M.; Fareed, J.; Pifarré, R.; The Annals of thoracic surgery
  • Heparan sulphate inhibition of cell proliferation induced by TGFbeta and PDGF. Silber, L. E.; Walenga, J. M.; Fareed, J.; Kovacs, E. J.; Mediators of inflammation
  • Postoperative monitoring of low molecular weight heparin prophylaxis in high-risk patients. Bacher, P.; Horst, B.; Breyer, H. G.; Hoppensteadt, D. A.; Walenga, J. M.; Fareed, J.; Seminars in thrombosis and hemostasis
  • Practical issues on the laboratory monitoring of low molecular weight heparins and related polysaccharides. Walenga, J. M.; Seminars in thrombosis and hemostasis
  • In vivo study of bleeding and antithrombotic effects of low molecular weight heparin ML-009723. Malinowska, K.; Iqbal, O.; Hoppensteadt, D. A.; Walenga, J. M.; Fareed, J.; Seminars in thrombosis and hemostasis
  • Evaluation of hematologic alterations associated with daily administration of low molecular weight heparin (Mono-Embolex) for a 12-week period. Lojewski, B.; Bacher, P.; Iqbal, O.; Walenga, J. M.; Hoppensteadt, D. A.; Leya, F.; Fareed, J.; Seminars in thrombosis and hemostasis
  • Biochemical and pharmacologic profile of low molecular weight heparin (LU 47311, Clivarin). Jeske, W.; Lojewski, B.; Walenga, J. M.; Hoppensteadt, D.; Ahsan, A.; Fareed, J.; Seminars in thrombosis and hemostasis
  • A comparison of the pharmacokinetic and pharmacodynamic profiles of Clexane and Lovenox in dogs. Iqbal, O.; Jeske, W.; Bacher, P.; Hoppensteadt, D. A.; Walenga, J. M.; Fareed, J.; Seminars in thrombosis and hemostasis
  • Current perspectives on low molecular weight heparins. Fareed, J.; Hoppensteadt, D. A.; Walenga, J. M.; Seminars in thrombosis and hemostasis
  • A new approach in monitoring recombinant hirudin during cardiopulmonary bypass. Koza, M. J.; Walenga, J. M.; Fareed, J.; Pifarre, R.; Seminars in thrombosis and hemostasis
  • Low molecular weight heparins. An objective overview. Hoppensteadt, D.; Walenga, J. M.; Fareed, J.; Drugs & aging
  • Tracheal and bronchial cartilaginous rings: warfarin sodium-induced calcification. Moncada, R. M.; Venta, L. A.; Venta, E. R.; Fareed, J.; Walenga, J. M.; Messmore, H. L.; Radiology
  • The effect of burn wound size on hemostasis: a correlation of the hemostatic changes to the clinical state. Kowal-Vern, A.; Gamelli, R. L.; Walenga, J. M.; Hoppensteadt, D.; Sharp-Pucci, M.; Schumacher, H. R.; The Journal of trauma
  • Pharmacological modulation of fibrinolysis by antithrombotic and cardiovascular drugs. Fareed, J.; Bacher, P.; Messmore, H. L.; Walenga, J. M.; Hoppensteadt, D. A.; Strano, A.; Pifarre, R.; Progress in cardiovascular diseases
  • Hemostatic abnormalities in total artificial heart patients as detected by specific blood markers. Walenga, J. M.; Hoppensteadt, D.; Fareed, J.; Pifarré, R.; The Annals of thoracic surgery
  • The thrombolytic potency of LMW-heparin compared to urokinase in a rabbit jugular vein clot lysis model. Bacher, P.; Welzel, D.; Iqbal, O.; Hoppensteadt, D.; Callas, D.; Walenga, J. M.; Fareed, J.; Thrombosis research
  • Some objective considerations for the use of heparins and recombinant hirudin in percutaneous transluminal coronary angioplasty. Fareed, J.; Walenga, J. M.; Leya, F.; Bacher, P.; Hoppensteadt, D.; Messmore, H.; Pifarre, R.; Seminars in thrombosis and hemostasis
  • Neutralization of recombinant hirudin: some practical considerations. Fareed, J.; Walenga, J. M.; Hoppensteadt, D.; Iyer, L.; Pifarre, R.; Seminars in thrombosis and hemostasis
  • Comparative studies on various assays for the laboratory evaluation of r-hirudin. Walenga, J. M.; Hoppensteadt, D.; Koza, M.; Pifarre, R.; Fareed, J.; Seminars in thrombosis and hemostasis
  • Potential use of recombinant hirudin as an anticoagulant in a cardiopulmonary bypass model. Walenga, J. M.; Bakhos, M.; Messmore, H. L.; Fareed, J.; Pifarre, R.; The Annals of thoracic surgery
  • An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agent. Fareed, J.; Walenga, J. M.; Iyer, L.; Hoppensteadt, D.; Pifarre, R.; Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  • Comparison of recombinant hirudin and heparin as an anticoagulant in a cardiopulmonary bypass model. Walenga, J. M.; Bakhos, M.; Messmore, H. L.; Koza, M.; Wallock, M.; Orfei, E.; Fareed, J.; Pifarre, R.; Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  • Use of recombinant hirudin to increase the patency rate of microanastomosis in a rabbit model. Hubbard, T.; Olivier, T.; Bacher, P.; Walenga, J. M.; Galal, H.; Fareed, J.; Pifarre, R.; Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  • Effect of dermatan sulfate and heparan sulfate on platelet activity compared to heparin. Hoppensteadt, D. A.; Walenga, J. M.; Fareed, J.; Seminars in thrombosis and hemostasis
  • Molecular and functional heterogeneity in dermatan sulfate preparations. Fareed, J.; Hoppensteadt, D.; Walenga, J. M.; Ahsan, A.; Coyne, E.; Breddin, H. K.; Seminars in thrombosis and hemostasis
  • Protamine sulfate neutralization of lactobionic acid amides. Hoppensteadt, D.; Walenga, J. M.; Fareed, J.; Seminars in thrombosis and hemostasis
  • Pharmacodynamics of a sulfated lactobionic acid amide-derived antithrombotic agent (Aprosulate) in primates. Fareed, J.; Coker, S.; Iqbal, O.; Hoppensteadt, D.; Walenga, J. M.; Seminars in thrombosis and hemostasis
  • Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudin. Fareed, J.; Walenga, J. M.; Pifarre, R.; Hoppensteadt, D.; Koza, M.; Haemostasis
  • Laboratory assays for the evaluation of recombinant hirudin. Walenga, J. M.; Hoppensteadt, D.; Koza, M.; Wallock, M.; Pifarre, R.; Fareed, J.; Haemostasis
  • Non-heparin glycosaminoglycan-derived drugs: a biochemical and pharmacologic perspective. Walenga, J. M.; Hoppensteadt, D.; Fareed, J.; Seminars in thrombosis and hemostasis
  • Behavioral, endocrine, and neurochemical effects of sulfomucopolysaccharide treatment in the aged Fischer 344 male rat. Lorens, S. A.; Guschwan, M.; Hata, N.; van de Kar, L. D.; Walenga, J. M.; Fareed, J.; Seminars in thrombosis and hemostasis
  • Experimental and clinical validation of the prophylactic antithrombotic effects of a low molecular weight heparin (enoxaparin). Fareed, J.; Walenga, J. M.; Hoppensteadt, D.; Borris, L. C.; Lassen, M. R.; Seminars in thrombosis and hemostasis
  • Laboratory monitoring of the clinical effects of low molecular weight heparins. Walenga, J. M.; Hoppensteadt, D.; Fareed, J.; Thrombosis research. Supplement
  • Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparin. Hoppensteadt, D.; Walenga, J. M.; Fareed, J.; Thrombosis research
  • Global and molecular hemostatic markers in acute myeloid leukemia. Reddy, V. B.; Kowal-Vern, A.; Hoppensteadt, D. A.; Kumar, A.; Walenga, J. M.; Fareed, J.; Schumacher, H. R.; American journal of clinical pathology
  • Thrombogenic potential of nonionic contrast media? Fareed, J.; Walenga, J. M.; Saravia, G. E.; Moncada, R. M.; Radiology
  • Pharmacologic profile of a low molecular weight heparin (enoxaparin): experimental and clinical validation of the prophylactic antithrombotic effects. Fareed, J.; Walenga, J. M.; Lassen, M.; Borris, L.; Hoppensteadt, D.; Murphy, R.; Ahsan, A.; Weber, S.; Jorgensen, L. N.; Hauch, O.; Acta chirurgica Scandinavica. Supplementum
  • Chemical and biological heterogeneity in low molecular weight heparins: implications for clinical use and standardization. Fareed, J.; Walenga, J. M.; Hoppensteadt, D.; Racanelli, A.; Coyne, E.; Seminars in thrombosis and hemostasis
  • Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate, and heparin. Hoppensteadt, D.; Racanelli, A.; Walenga, J. M.; Fareed, J.; Seminars in thrombosis and hemostasis
  • Development of recombinant hirudin as a therapeutic anticoagulant and antithrombotic agent: some objective considerations. Walenga, J. M.; Pifarre, R.; Hoppensteadt, D. A.; Fareed, J.; Seminars in thrombosis and hemostasis
  • Antithrombotic drugs in pelvic surgery. Fareed, J.; Walenga, J. M.; Cornelli, U.; Seminars in thrombosis and hemostasis
  • Biochemical and pharmacologic inequivalence of low molecular weight heparins. Fareed, J.; Walenga, J. M.; Hoppensteadt, D.; Huan, X.; Nonn, R.; Annals of the New York Academy of Sciences
  • Importance of a 3-O-sulfate group in a heparin pentasaccharide for antithrombotic activity. Walenga, J. M.; Petitou, M.; Samama, M.; Fareed, J.; Choay, J.; Thrombosis research
  • Aggregates in heparin. Coyne, E.; Walenga, J. M.; Fareed, J.; Journal of pharmaceutical sciences
  • The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity. Walenga, J. M.; Bara, L.; Petitou, M.; Samama, M.; Fareed, J.; Choay, J.; Thrombosis research
  • Validity of the newly established low-molecular-weight heparin standard in cross-referencing low-molecular-weight heparins. Fareed, J.; Walenga, J. M.; Racanelli, A.; Hoppensteadt, D.; Huan, X.; Messmore, H. L.; Haemostasis
  • Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins. Fareed, J.; Walenga, J. M.; Hoppensteadt, D.; Huan, X.; Racanelli, A.; Haemostasis
  • Pharmacologic profiling of defibrotide in experimental models. Fareed, J.; Walenga, J. M.; Hoppensteadt, D. A.; Kumar, A.; Ulutin, O. N.; Cornelli, U.; Seminars in thrombosis and hemostasis
888-584-7888

Dismiss Modal

Close 

Where would you like to share?